Your browser doesn't support javascript.
loading
Circulating miR-30b-5p levels in plasma as a novel potential biomarker for early detection of breast cancer.
Adam-Artigues, A; Garrido-Cano, I; Simón, S; Ortega, B; Moragón, S; Lameirinhas, A; Constâncio, V; Salta, S; Burgués, O; Bermejo, B; Henrique, R; Lluch, A; Jerónimo, C; Eroles, P; Cejalvo, J M.
Afiliação
  • Adam-Artigues A; Biomedical Research Institute INCLIVA, Valencia, Spain.
  • Garrido-Cano I; Biomedical Research Institute INCLIVA, Valencia, Spain.
  • Simón S; Biomedical Research Institute INCLIVA, Valencia, Spain; Clinical Oncology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain.
  • Ortega B; Biomedical Research Institute INCLIVA, Valencia, Spain; Clinical Oncology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain.
  • Moragón S; Biomedical Research Institute INCLIVA, Valencia, Spain; Clinical Oncology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain.
  • Lameirinhas A; Biomedical Research Institute INCLIVA, Valencia, Spain.
  • Constâncio V; Cancer Biology and Epigenetics Group Research Center, Portuguese Oncology Institute of Porto (CI-IPOP), Porto, Portugal.
  • Salta S; Cancer Biology and Epigenetics Group Research Center, Portuguese Oncology Institute of Porto (CI-IPOP), Porto, Portugal.
  • Burgués O; Biomedical Research Institute INCLIVA, Valencia, Spain; Clinical Oncology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
  • Bermejo B; Biomedical Research Institute INCLIVA, Valencia, Spain; Clinical Oncology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
  • Henrique R; Cancer Biology and Epigenetics Group Research Center, Portuguese Oncology Institute of Porto (CI-IPOP), Porto, Portugal; Department of Pathology, Portuguese Oncology Institute of Porto, Porto, Portugal; Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar U
  • Lluch A; Clinical Oncology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Department of Medicine, Universitat de València, Valencia, Spain.
  • Jerónimo C; Cancer Biology and Epigenetics Group Research Center, Portuguese Oncology Institute of Porto (CI-IPOP), Porto, Portugal; Department of Pathology, Portuguese Oncology Institute of Porto, Porto, Portugal; Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar U
  • Eroles P; Biomedical Research Institute INCLIVA, Valencia, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Department of Physiology, Universitat de València, València, Spain. Electronic address: pilar.eroles@uv.es.
  • Cejalvo JM; Biomedical Research Institute INCLIVA, Valencia, Spain; Clinical Oncology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. Electronic address: jmcejalvo@incliva.es.
ESMO Open ; 6(1): 100039, 2021 02.
Article em En | MEDLINE | ID: mdl-33477007

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias da Mama / MicroRNAs Tipo de estudo: Diagnostic_studies / Prognostic_studies / Screening_studies Limite: Female / Humans Idioma: En Revista: ESMO Open Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias da Mama / MicroRNAs Tipo de estudo: Diagnostic_studies / Prognostic_studies / Screening_studies Limite: Female / Humans Idioma: En Revista: ESMO Open Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Espanha